• Citer

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

par Dimopoulos, Meletios Athanassios;Oriolo, Anna;Nahi, Hareth;San-Miguel, Jesus;Bahlis, Nizar NJ;Usmani, Saad SZ;Rabinovitch Mahler, N.;ORLOWSKI, Ronald R.C.;Komarnicki, Mieczyslaw;Suzuki, K;Plesner, Torben;Yoon, Sungchul S.C.;Ben Yehuda, Dina;Richardson, Paul P.G.;Goldschmidt, Hartmut;Reece, Donna;Lisby, Steen;Khokhar, Nushmia NZ;O'Rourke, Lisa;Chiu, Charles C.B.;Qin, Xiang;Guckert, Mary;Ahmadi, Tahamtan;Moreau, Pascale ;POLLUX Investigators,
Référence The New England journal of medicine, 375, 14, page (1319-1331)
Publication Publié, 2016

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma.